Sather Financial Group Inc Boosts Holdings in Abbott Laboratories $ABT

Sather Financial Group Inc grew its stake in shares of Abbott Laboratories (NYSE:ABT) by 59.2% in the second quarter, Holdings Channel reports. The firm owned 3,227 shares of the healthcare product maker’s stock after acquiring an additional 1,200 shares during the period. Sather Financial Group Inc’s holdings in Abbott Laboratories were worth $439,000 at the end of the most recent quarter.

A number of other large investors have also recently made changes to their positions in ABT. Brighton Jones LLC boosted its stake in shares of Abbott Laboratories by 10.1% during the fourth quarter. Brighton Jones LLC now owns 51,719 shares of the healthcare product maker’s stock valued at $5,850,000 after purchasing an additional 4,755 shares during the period. GAMMA Investing LLC boosted its stake in shares of Abbott Laboratories by 17.0% during the first quarter. GAMMA Investing LLC now owns 38,467 shares of the healthcare product maker’s stock valued at $5,103,000 after purchasing an additional 5,590 shares during the period. West Branch Capital LLC boosted its stake in shares of Abbott Laboratories by 13.3% during the first quarter. West Branch Capital LLC now owns 17,677 shares of the healthcare product maker’s stock valued at $2,345,000 after purchasing an additional 2,080 shares during the period. CVA Family Office LLC raised its holdings in shares of Abbott Laboratories by 2.5% in the first quarter. CVA Family Office LLC now owns 7,555 shares of the healthcare product maker’s stock valued at $1,002,000 after acquiring an additional 183 shares in the last quarter. Finally, Goldstone Financial Group LLC raised its holdings in shares of Abbott Laboratories by 39.8% in the first quarter. Goldstone Financial Group LLC now owns 13,901 shares of the healthcare product maker’s stock valued at $1,844,000 after acquiring an additional 3,954 shares in the last quarter. 75.18% of the stock is owned by hedge funds and other institutional investors.

Abbott Laboratories Stock Performance

ABT opened at $132.30 on Friday. Abbott Laboratories has a 52-week low of $110.86 and a 52-week high of $141.23. The firm’s 50-day moving average price is $132.54 and its 200-day moving average price is $131.60. The company has a quick ratio of 1.30, a current ratio of 1.82 and a debt-to-equity ratio of 0.25. The company has a market cap of $230.26 billion, a P/E ratio of 16.58, a price-to-earnings-growth ratio of 2.51 and a beta of 0.69.

Abbott Laboratories (NYSE:ABT) last issued its quarterly earnings results on Thursday, July 17th. The healthcare product maker reported $1.26 earnings per share for the quarter, hitting the consensus estimate of $1.26. Abbott Laboratories had a net margin of 32.43% and a return on equity of 18.32%. The company had revenue of $11.14 billion for the quarter, compared to the consensus estimate of $11.01 billion. During the same quarter in the prior year, the company earned $1.14 EPS. Abbott Laboratories’s quarterly revenue was up 7.4% on a year-over-year basis. Abbott Laboratories has set its FY 2025 guidance at 5.100-5.200 EPS. Q3 2025 guidance at 1.280-1.320 EPS. As a group, equities analysts anticipate that Abbott Laboratories will post 5.14 EPS for the current fiscal year.

Abbott Laboratories Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Monday, November 17th. Stockholders of record on Wednesday, October 15th will be given a dividend of $0.59 per share. The ex-dividend date is Wednesday, October 15th. This represents a $2.36 dividend on an annualized basis and a dividend yield of 1.8%. Abbott Laboratories’s dividend payout ratio (DPR) is 29.57%.

Analyst Ratings Changes

Several research firms recently weighed in on ABT. Morgan Stanley lifted their price objective on Abbott Laboratories from $127.00 to $137.00 and gave the company an “equal weight” rating in a report on Tuesday, July 15th. Raymond James Financial decreased their price objective on Abbott Laboratories from $142.00 to $141.00 and set an “outperform” rating for the company in a report on Friday, July 18th. Evercore ISI lifted their price objective on Abbott Laboratories from $140.00 to $144.00 and gave the company an “outperform” rating in a report on Tuesday, October 7th. Royal Bank Of Canada lifted their price objective on Abbott Laboratories from $145.00 to $147.00 and gave the company an “outperform” rating in a report on Tuesday, July 15th. Finally, BTIG Research decreased their price objective on Abbott Laboratories from $148.00 to $145.00 and set a “buy” rating for the company in a report on Friday, July 18th. Two analysts have rated the stock with a Strong Buy rating, sixteen have issued a Buy rating and four have given a Hold rating to the stock. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average price target of $146.17.

Insider Activity

In other news, CFO Philip P. Boudreau sold 5,550 shares of the stock in a transaction that occurred on Friday, August 8th. The stock was sold at an average price of $134.55, for a total transaction of $746,752.50. Following the transaction, the chief financial officer owned 51,003 shares in the company, valued at $6,862,453.65. This trade represents a 9.81% decrease in their position. The sale was disclosed in a filing with the SEC, which is available at the SEC website. 0.46% of the stock is owned by company insiders.

Abbott Laboratories Company Profile

Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière’s disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon.